Skip to main content
. Author manuscript; available in PMC: 2013 Apr 16.
Published in final edited form as: Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925

Fig. 7.

Fig. 7

Immunogenicity of human and chimpanzee adenovirus in humans. IFNγ ELISpot data from human healthy volunteers vaccinated once with the indicated dosage of HCV adenovirus vaccines Ad6-NSmut (n=9, (30)) and ChAd3-NSmut (n=10, (30)) or malaria adenovirus vaccine ChAd63-METRAP (n=39, (31, 32)) are shown as mean+SEM of individual responses to the vaccine inserts (A). Individual responses are obtained by summing each volunteer’s reactivity to peptide pools (six pools for the HCV NS region and six pools for TRAP plus one pool for ME regions of the Malaria vaccine insert). Peak response was measured two or four weeks after vaccination. Dot plots showing IFNγ secretion by CD4 and CD8 T cells from two representative volunteers vaccinated with Ad6 or ChAd3 HCV vaccine vectors are shown in (B). PBMC were stimulated with either a mixture of the three HCV NS pools covering NS3 and NS4 region of the HCV vaccine insert (NS3-4), or with DMSO, the peptide pool diluent, as negative control. Numbers in each plot correspond to frequency of IFNγ + cells over total CD4 and CD8.